Literature DB >> 9215616

Deoxycytidine kinase mRNA expression in childhood acute lymphoblastic leukemia.

G Stammler1, F Zintl, A Sauerbrey, M Volm.   

Abstract

Initial and relapsed childhood acute lymphoblastic leukemias (ALL) were investigated for mutations and expression of deoxycytidine kinase (dCK). dCK mediating toxicity of 1-beta-D-arabinofuranosylcytosine was analyzed semiquantitatively by RT-PCR and by single-strand conformation polymorphism. We found that patients with initial ALL experienced more frequently a relapse if dCK expression was low or absent. No mutations were found in initial and relapsed ALL.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9215616     DOI: 10.1097/00001813-199706000-00015

Source DB:  PubMed          Journal:  Anticancer Drugs        ISSN: 0959-4973            Impact factor:   2.248


  4 in total

Review 1.  Pharmacogenomics in pediatric leukemia.

Authors:  Steven W Paugh; Gabriele Stocco; William E Evans
Journal:  Curr Opin Pediatr       Date:  2010-12       Impact factor: 2.856

2.  Mechanisms of resistance to 5-aza-2'-deoxycytidine in human cancer cell lines.

Authors:  Taichun Qin; Jaroslav Jelinek; Jiali Si; Jingmin Shu; Jean-Pierre J Issa
Journal:  Blood       Date:  2008-10-17       Impact factor: 22.113

Review 3.  Management of colorectal cancer.

Authors:  A Leslie; R J C Steele
Journal:  Postgrad Med J       Date:  2002-08       Impact factor: 2.401

4.  Clofarabine exerts antileukemic activity against cytarabine-resistant B-cell precursor acute lymphoblastic leukemia with low deoxycytidine kinase expression.

Authors:  Meixian Huang; Takeshi Inukai; Kunio Miyake; Yoichi Tanaka; Keiko Kagami; Masako Abe; Hiroaki Goto; Masayoshi Minegishi; Shotaro Iwamoto; Eiji Sugihara; Atsushi Watanabe; Shinpei Somazu; Tamao Shinohara; Hiroko Oshiro; Koshi Akahane; Kumiko Goi; Kanji Sugita
Journal:  Cancer Med       Date:  2018-02-23       Impact factor: 4.452

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.